|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003591,
umls-concept:C0004153,
umls-concept:C0011847,
umls-concept:C0021368,
umls-concept:C0025914,
umls-concept:C0026336,
umls-concept:C0026809,
umls-concept:C0205179,
umls-concept:C0242606,
umls-concept:C0360714,
umls-concept:C0598528,
umls-concept:C0599946,
umls-concept:C0717550,
umls-concept:C0815017,
umls-concept:C0965129,
umls-concept:C1280500
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-8-6
|
|
pubmed:abstractText |
We evaluated the anti-atherosclerotic effect of the 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, rosuvastatin, and the angiotensin II receptor blocker (ARB), candesartan, alone and in combination, in the streptozotocin-induced diabetic apolipoprotein E-deficient (Apoe (-/-)) mouse.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins E,
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorobenzenes,
http://linkedlifedata.com/resource/pubmed/chemical/Glycosylation End Products, Advanced,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/candesartan,
http://linkedlifedata.com/resource/pubmed/chemical/rosuvastatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0012-186X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1731-40
|
|
pubmed:meshHeading |
pubmed-meshheading:18594792-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:18594792-Animals,
pubmed-meshheading:18594792-Apolipoproteins E,
pubmed-meshheading:18594792-Benzimidazoles,
pubmed-meshheading:18594792-Blood Vessels,
pubmed-meshheading:18594792-Diabetes Mellitus,
pubmed-meshheading:18594792-Disease Models, Animal,
pubmed-meshheading:18594792-Fluorobenzenes,
pubmed-meshheading:18594792-Glycosylation End Products, Advanced,
pubmed-meshheading:18594792-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:18594792-Inflammation,
pubmed-meshheading:18594792-Mice,
pubmed-meshheading:18594792-Mice, Inbred C57BL,
pubmed-meshheading:18594792-Mice, Knockout,
pubmed-meshheading:18594792-Oxidative Stress,
pubmed-meshheading:18594792-Pyrimidines,
pubmed-meshheading:18594792-Sulfonamides,
pubmed-meshheading:18594792-Tetrazoles
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
|
|
pubmed:affiliation |
Diabetes Complications Laboratory, Baker Heart Research Institute, P.O. Box 6492, St Kilda Rd Central, Melbourne 8008, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
